Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 9/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 5/20 | 0.41 |
| ▸ | NPY1R | P25929 | 4/20 | 0.41 |
| ▸ | NPY2R | P49146 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29625226 | 0.96 | ENPEP (0.45) | ENPEPBACE1NPY4RNPY1RNPY2R | |
| SCHEMBL29625204 | 0.94 | NPY4R (0.43) | ENPEPBACE1NPY4RNPY1RNPY2R | |
| SCHEMBL29625213 | 0.90 | NPY4R (0.44) | ENPEPBACE1NPY4RNPY1RNPY2R | |
| SCHEMBL22687904 | 0.89 | NPY4R (0.41) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL29625209 | 0.89 | ENPEP (0.48) | ENPEP | |
| SCHEMBL29524799 | 0.87 | BACE1 (0.42) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL31206359 | 0.87 | NPY4R (0.46) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL29911841 | 0.87 | BACE1 (0.45) | ENPEPBACE1CTSDNPY4RNPY1R | |
| SCHEMBL30839890 | 0.86 | NPY4R (0.42) | BACE1CTSDNPY4RNPY1RNPY2R | |
| SCHEMBL29679761 | 0.86 | BACE1 (0.47) | BACE1CTSDNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220257698-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LANTHIOPEP B.V. (NL) | 2022-08-18 | — | — | US | disclosed |
| EP-4007592-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LanthioPep B.V. (NL) | 2022-06-08 | — | — | EP | disclosed |
| CN-114514032-A | Angiotensin type 2 (AT2) receptor agonists for the treatment of cancer | 兰提欧派普有限公司 | 2022-05-17 | — | — | CN | disclosed |